June 2022 Vol 13, No 6
On behalf of all of us at the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Journal of Oncology Navigation & Survivorship (JONS), I’d like to personally invite you to submit an abstract for the 13th Annual Navigation & Survivorship Conference to be held in New Orleans, LA, November 2-6, 2022. This is an opportunity to share your evidence-based navigation research studies, quality improvement projects, and best practices utilizing pre- and postdata elements to enhance your program with your navigation and survivorship care colleagues.
Breast Cancer Screening Among Women with Comorbidities: A Cross-Sectional Examination of Disparities from the Behavioral Risk Factor Surveillance System
Ashton Gatewood, MPH, BSN, RN, Mackenzie Enmeier, BS, Elise Stephenson, BA, Jordyn Austin, BS, Benjamin Greiner, DO, MPH, Micah Hartwell, PhD
Do comorbid diagnoses affect breast cancer screening rates? The authors of this study present their findings.
As a little girl, Tamika Felder dreamed of being on TV. She loved watching the news even at a very young age, had an unwavering curiosity about what was going on in the world, and set her sights on a career in television, which she later achieved. What she didn’t set her sights on was a cervical cancer diagnosis at the age of 25, a radical hysterectomy, and the devastating complete loss of her fertility.
The National Navigation Acuity Team – a collaborative initiative between AONN+ and Astellas – is developing an acuity tool to optimize patient care.
How are you explaining the nuances – and managing expectations – of genetic testing and precision medicine?
Data from electronic health records can successfully be used as infrastructure to mitigate cancer treatment disparities. Here’s how.
The tenets of navigation have significantly improved oncology patient care – and nurses in other specialties have taken note. Here’s what’s in their future.
Are you prepared to discuss fertility preservation with your patients?
Over the past 5 years, there have been 20 FDA approvals of novel genetic medicine technologies – and this is just the beginning. Here’s a glimpse of what’s coming ahead.
Results 1 - 9 of 9